Latest Regulatory Approval News

Alurion Resources has closed its IPO at the maximum subscription of A$50 million, setting the stage for an expanded development program at its Amargosa Bauxite-Gallium Project. Brazilian Rare Earths retains a strategic 16% stake as Alurion prepares for ASX listing.

Beach Energy delivered a solid FY26 with 19.4 MMboe production, a record 18 months without injuries, and a key Otway Basin asset sale freeing $500 million capital.

Cambium Bio has raised just over A$1 million through a strategic placement at a 17% premium, boosting a key shareholder’s stake as it advances its pivotal Phase 3 trial for dry eye disease.

NH3 Clean Energy has completed critical environmental surveys for its WAH2 Project, confirming no threatened species or ecological communities in the development area. This milestone supports upcoming State and Commonwealth approval submissions, advancing the project towards its final investment decision.

Optiscan Imaging has kicked off a US clinical trial with Mayo Clinic to test its InVue and InForm devices in breast conserving surgery, aiming to generate data for FDA 510(k) submissions and validate a new surgical-pathology workflow.

Radiopharm Theranostics reported robust Phase 2b results for RAD101 in brain metastases imaging, hitting 93% concordance with MRI and setting the stage for a U.S. Phase 3 trial. Meanwhile, its Phase 1 trial of RAD204 showed durable partial responses and good tolerability in advanced solid tumors.

Medallion Metals has signed a non-binding Term Sheet with TG Metals to process 60,000 tonnes of gold stockpiles at its Cosmic Boy Concentrator, sharing pre-tax profits equally after cost recovery. This deal complements Medallion’s Early Production Strategy and will not disrupt its Ravensthorpe project timeline.

Union Star Metals has agreed to sell its Brazilian rare earth subsidiary to Harvest Minerals, receiving cash, shares, and milestone payments while sharpening its focus on gold and silver exploration in the US.

SkyCity Entertainment Group has signed a non-binding heads of agreement to sell The Grand Hotel, aiming to boost financial flexibility through asset monetisation and debt repayment.

Ceretas Limited is raising $8 million through an IPO to fund clinical trials and development of its novel therapeutic ultrasound device targeting Alzheimer’s disease symptoms.

Recce Pharmaceuticals secured a non-binding term sheet with a major Middle Eastern pharma for its diabetic foot infection treatment and raised A$4 million to fund pivotal Phase 3 trials in Australia and Indonesia.

Silver Mines has confirmed robust economics for its Bowdens Silver Project, boosting ore reserves to 93.5 million ounces and outlining a 26-year mine life with a $455 million capital cost estimate.